The Efficacy of Orally Administered GSK2190915 as an Add-on to Current Therapy in Subjects With Moderate to Severe Asthma Who Have Elevated Sputum Neutrophils.

Trial Profile

The Efficacy of Orally Administered GSK2190915 as an Add-on to Current Therapy in Subjects With Moderate to Severe Asthma Who Have Elevated Sputum Neutrophils.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 Dec 2016

At a glance

  • Drugs Fiboflapon (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 11 Mar 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 09 Jul 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top